AI powered cough tracking app Hyfe announces partnership with ObvioHealth to assist in virtual clinical trials and illness diagnosis
UNITED STATES - Innovative AI cough tracking app Hyfe, has, today, announced a new partnership with global virtual research organisation ObvioHealth. This latest collaboration is set to see coughing frequency, severities and types monitored by Hyfe incorporated into virtual clinic trials. It is hoped this partnership will better assist clinical researchers in identifying different strains of coughs and adjoining illnesses, including long COVID in a post-pandemic world.
Hyfe is an Artificial Intelligence platform that runs on any smartphone and detects and tracks coughs as they happen. Hyfe’s technology is unique in that it achieves high accuracy in detecting coughs in the real world: it can run across a wide range of hardware, devices and operating systems and it performs in environments with significant levels of background noise .
This partnership will see Hyfe’s technology integrated into ObvioHealth’s decentralised clinical trials platform. Data will be collected in real time and transmitted to a dashboard, enabling healthcare professionals and researchers to analyze coughing frequency, severity, and type. The Hyfe-ObvioHealth collaboration aims to enhance data collection and evaluation capabilities that can improve the measurement of symptoms.
Hyfe is a Delaware, US company that employs over 20 staff remotely. Founded just over one year ago, Hyfe is already deployed in more than 20 clinical research sites all over the world, including as part of a ground-breaking Acoustic Epidemiological study in collaboration with the University of Navarra in spain, that monitors and analyzes cough frequency at population/ community level. As part of this study, Hyfe’s technology helped identify several respiratory conditions and helped participants with treatment. It even helped predict disease in a few cases, days before patients receiving diagnosis, simply based on changes in cough frequency patterns.
According to WHO statistics, respiratory diseases are among the leading causes of death and disability in the world, with figures revealing around 334 million people suffer from asthma worldwide. In addition to this, research by The Lancet has revealed millions die prematurely every year from tuberculosis, pneumonia, lung cancer and other chronic respiratory illnesses. Hyfe aims to use its technology to help curb the further spread of COVID-19 and identify signs of long COVID, as over 167 million cases of coronavirus have been confirmed globally.
When it comes to AI and healthcare, a joint report published by the European Union’s EIT and Mckinsey states that artificial intelligence tools can enable healthcare systems to provide better care to more people. Furthermore, AI can help improve the experience of healthcare practitioners, enabling them to spend more time in direct patient care, therefore reducing burnout.
Commenting on the significance of the partnership, Joe Brew, CEO and Co-founder of Hyfe, said: “This latest partnership with ObvioHealth will enable cough tracking to become a significant part of virtual clinical trials and provide further insight into how coughs can indicate serious illness and whether someone is suffering from long COVID. Our coughing diagnostic tool reveals patterns and correlations, giving clinical researchers an unprecedented level of fidelity. We are thrilled to begin Hyfe’s next phase, and we’re confident that our collaboration with ObvioHealth will lead to significant developments in our acoustic diagnostics technology, as well as demonstrate real benefit to individual health awareness.”
CEO of ObvioHealth, Ivan Jarry, said: “These digital instruments are improving the way data is collected and analyzed for clinical research. Not only do these tools reduce the burden on study participants and deliver more accurate data, they also open the door to new and deeper ways to analyze unstructured data that will deliver novel outcomes going forward. That is why we’re so excited to announce our partnership with Hyfe and are already seeing the fruits of collaboration.”
- ENDS -
Hyfe is an artificial intelligence company that builds acoustic detection and diagnostics tools for respiratory conditions. Hyfe’s cough detection models can run on any smartphone and are used daily by researchers, medical professionals as well as thousands of regular people all over the world.
For more information, visit https://hyfe.ai
ObvioHealth is an end-to-end Virtual Research Organization (VRO) that delivers better data to sponsors and an easier clinical trial experience for participants. The company developed and launched one of the first DCT apps, downloadable on smartphones enabling people to participate in clinical trials from the comfort of their homes. In the 3 years since launch, the company has been awarded nearly 40 studies from 22 blue chip clients, implemented in 28 countries, in 16 different therapeutic areas. For more information, visit www.obviohealth.com.
Imagine a World In Which Monitoring Cough Frequency can Predict and Prevent COPD Exacerbations
Cough is prevalent across diseases yet its tracking has been elusive, stalling scientific advancements. Hyfe's tech is changing this - we're now able to analyze objective cough data & predict risk.
Hyfe AI and ActiGraph Partner to Revolutionize Clinical Trials with AI-Powered Cough Detection
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Hyfe AI Announces New Remote Cough Monitoring Integration, Aiding to Reduce Patient Hospitalization and Improve Virtual Care
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.